Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365985 · ClinicalTrials.gov registry record · Phase 2
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
A Phase 2 study, sponsored by Corewell Health East.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT04365985 is a Phase 2 study that was terminated before completion, run by Corewell Health East. The registered enrollment target is 70 participants.
The verdict
NCT04365985, a Phase 2 study, was terminated before completion, sponsored by Corewell Health East.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.
Interventions
- OTHER Placebo
- DRUG Ketamine
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-04-29 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04365985
The ClinicalTrials.gov registry entry for NCT04365985 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04365985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04365985 about?
NCT04365985 is a clinical study titled "Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19". Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available i...
What is the current status of trial NCT04365985?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2020-04-29. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04365985?
The interventions under investigation include: Placebo (OTHER), Ketamine (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT04365985?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.